Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Ho C, Gopal AK, Till BG, Shadman M, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Cassaday RD, Fromm JR, Fang M, Smith SD. Ho C, et al. Among authors: ujjani cs. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e33-e39.e1. doi: 10.1016/j.clml.2023.10.002. Epub 2023 Oct 18. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37926672
Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours.
Mato AR, Luger SM, Heitjan DF, Mikkelsen ME, Olson E, Ujjani C, Jacobs S, Miltiades AN, Shah P, Schuster SJ, Carroll M, Chauffe AD, Fuchs BD. Mato AR, et al. Cancer Biol Ther. 2010 Apr 15;9(8):585-9. doi: 10.4161/cbt.9.8.11270. Epub 2010 Apr 20. Cancer Biol Ther. 2010. PMID: 20160493 Free article.
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M. Cooper JP, et al. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):390-395. doi: 10.1016/j.clml.2019.03.003. Epub 2019 Mar 11. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30948330
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, Smith SD, Till B, Lynch RC, Ujjani C, Shadman M, Warren EH, Menon M, Russell K, Tseng YD. Kim A, et al. Pract Radiat Oncol. 2020 Jan-Feb;10(1):44-52. doi: 10.1016/j.prro.2019.09.013. Epub 2019 Oct 1. Pract Radiat Oncol. 2020. PMID: 31585205
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. Ujjani C, et al. Blood Lymphat Cancer. 2020 Aug 24;10:1-5. doi: 10.2147/BLCTT.S262592. eCollection 2020. Blood Lymphat Cancer. 2020. PMID: 32943973 Free PMC article.
61 results